Last reviewed · How we verify
NCT06359795
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
NA trial testing 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT in Thyroid Eye Disease in 50 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Peking University Third Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 50 |
| Start date | 15 December 2023 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT
Conditions studied
- Thyroid Eye Disease — all drugs for Thyroid Eye Disease →
Sponsor
Peking University Third Hospital
Who can join
Adults 18 to 80, any sex, with Thyroid Eye Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Evaluation of fibroinflammatory activity in thyroid eye disease using [<sup>18</sup>F]AlF-NOTA-FAPI-04 PET/CT: A prospective study.
Li H, Wang Y, Zhou J, You D, et al · · 2025 · cited 3× · PMID 39671100 · DOI 10.1007/s00259-024-07015-y
Verify or expand the search:
- PubMed search for NCT06359795
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Eye Disease
Currently open trials in the same condition.
- NCT07423013 — Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. · NA · recruiting
- NCT07113262 — A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease · Phase 3 · recruiting
- NCT06557850 — A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease · Phase 1 · active not recruiting
- NCT06625411 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
- NCT06625398 — An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) · Phase 3 · active not recruiting
Other Peking University Third Hospital trials
Trials by the same sponsor.
- NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
- NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
- NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
- NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
- NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06359795 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
- Last refreshed: 11 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06359795.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing